Gastric
& Breast Cancer e-journal
DOI: 10.2122/gbc.2006.0043
COMMENTARY
|
Antharacyclin-based
chemotherapy benefits breast cancer patients with
HER2 amplified or overexpressed tumours: new trial
adds on evidence towards individualized therapy.
|
Evangelos
Briasoulis, Dimosthenis Ziogas, Michael Fatouros,
Dimitrios H. Roukos and Angelos M. Kappas |
| Since
this article has no abstract we provide the first paragraph. |
Human
epidermal growth factor receptor 2 (HER2 or erbB2)
is an established molecular marker of prognosis
and responsiveness to breast cancer therapy. Randomized
evidence suggests that breast cancer patients with
HER2 amplified or overexpressed can benefit from
trastuzumab therapy [1-5]
|
|
|
|
Find Delta Dental, MetLife Dental, Aetna Dentist, New York Dentist, San Francisco Dentist, Boston Dentist, Chicago Dentist, Los Angeles Dentist & San Diego Dentist at DoctorsImprovingHealthcare.org. Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 3 February 2004 |
|
|
|
